Effects of Coenzyme Q10 in PSP and CBD

Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00532571

Enrollment

Unknown

Registered

2007-09-20

Start date

2004-01-31

Completion date

2005-09-30

Last updated

2018-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Disorders, Progressive Supranuclear Palsy

Keywords

CoQ10, PSP, CBD

Brief summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Interventions

DRUGCoQ10

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years * Age \> 40 * Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit. * Patients agreeable to participate in the study.

Exclusion criteria

* Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit. * Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs. * History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant. * Previous use of coenzyme Q10 within 60 days of the baseline visit.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026